Packed 180gsm polyester fleece emergency blankets in sealed trauma kit polybags on a factory inspection table

Why kit inclusion raises the question, but does not decide the answer

Distributors are right to ask for an ISO 10993 review when a blanket is supplied into a trauma or first-aid kit, but kit inclusion alone does not determine applicability. The trigger is intended use and contact characterisation within the finished product regulatory strategy. A general-use warmth blanket packed alongside medical items may remain a conventional textile from the supplier side, supported by a controlled BOM, chemical declarations and article-specific traceability. A blanket specified as part of patient management, especially where direct patient contact is intended, can become part of the biological evaluation under ISO 10993-1 used by the legal manufacturer placing the kit on the market.

Responsibility has to stay clear. The supplier can provide material disclosure, prior test reports, process descriptions, change-control commitments and declarations tied to the quoted article. The legal device classification decision, claim strategy, risk management linkage and final biological evaluation conclusion belong to the economic operator placing the finished kit on the market: typically the legal manufacturer, private-label owner or their regulatory function supported by a qualified assessor or toxicologist. A mill should not declare the article "approved for medical use" on its own authority, and a buyer should not accept that wording as a substitute for dossier review.

For sourcing decisions, classify the blanket in plain terms before asking for tests. Start with five questions: what exact claim appears on the kit and IFU, does the blanket contact intact skin only, is any contact with compromised skin claimed or reasonably foreseeable, which ISO 10993-1 contact-duration bucket is being defended, and what chemistry complexity exists in the finished article. For most emergency fleece blankets, the low-risk starting point is surface contact with intact skin for limited exposure of 24 hours or less. Once claims shift toward burn care, wound-adjacent use or direct placement over injured tissue, the evidence plan changes materially and brushed fleece may no longer be the right substrate.

Market context: FDA, EU MDR, UK MDR and destination-market ownership

Buyers need explicit regulatory caution here. U.S. FDA treatment, EU MDR treatment and UK MDR treatment depend on the specific finished kit, intended purpose, claims language, instructions, accessories, route to market and the legal manufacturer’s classification rationale. The same blanket construction may be acceptable as a general warmth component in one program and insufficient in another with different claims. Supplier reports support the file; they do not decide classification.

In the United States, a blanket sold standalone as a general warmth product may sit outside medical-device scope, while the same blanket included in a first-aid or trauma kit can still matter to the overall dossier if the kit marketer makes patient-care claims. Many U.S. buyers therefore request ISO 10993-style support even where the textile itself is not independently cleared. That is a finished-kit regulatory strategy issue, not proof that every kit blanket is itself a device requiring the same evidence route.

Under EU MDR and UK MDR, classification and evidence expectations depend on intended purpose, body contact, mode of action and how the finished set or kit is placed on the market. A blanket sold as a comfort or transport textile is a different case from a blanket promoted for thermal management during first aid, burn response or patient handling. If the article supports a regulated medical dossier, the legal manufacturer usually needs a risk-based biological evaluation under ISO 10993-1 using finished-article-specific information. The supplier contributes evidence, but cannot substitute for that evaluation.

For other destination markets, the pattern is similar even where the formal document set differs. Destination-market rules decide classification; the supplier provides component evidence matched to the exact article. Do not assume that a report accepted in one programme automatically satisfies another if claims, packaging configuration, sterilization status, patient contact or legal owner change.

Define the article before you discuss ISO 10993

Do not begin with "is it ISO 10993 certified". That wording is non-standard and it drives weak supplier behaviour. Ask for article definition first. For a typical OEM trauma-kit fleece, a workable baseline might be 100% polyester knit fleece at 180gsm with finished fabric mass tolerance around +/-5% as a commercial control, cut size tolerance around +/-2cm on a 120 x 150cm or 130 x 170cm blanket, 3-thread or 4-thread overlock in 150D to 300D polyester sewing thread, no topical antimicrobial or fragrance finish, no printed artwork in the main patient-contact area, and LDPE or HDPE polybag packaging with controlled odour and specified thickness such as 40 to 60 microns.

The point is change sensitivity. Polyester fleece is not one substance. The chemical profile can shift with disperse dyes, carrier systems, softeners, silicone emulsions, anti-pilling agents, flame-retardant additives, antimicrobial actives, print binders, heat-transfer labels, woven labels, hot-melt adhesives, recycled-content variability and even the inner polybag if it carries aggressive slip additives or residual odour. Buyers should request a BOM down to component and finish-family level where feasible, not just "polyester blanket".

Report matching needs the same discipline. Reject reports that differ from the quoted article in fabric weight, fibre source, recycled content, colour, print process, finish package, thread type, label construction, adhesive use, packaging film, sterilization status or contact claim. A cytotoxicity report on a 220gsm white undyed fleece with no print is weak support for a 180gsm black fleece with transfer print, woven hem label and a sealed retail polybag. The article definition has to stay locked long enough for evidence to mean anything.

If the programme is still at material-selection stage, adjacent references such as [blanket quality control inspection](/blog/blanket-quality-control-inspection.html), [custom-blanket-lead-times-shipping](/blog/custom-blanket-lead-times-shipping.html) and [oeko-tex-standard-100-for-custom-fleece-blankets-class-ii-vs-class-i-r](/blog/oeko-tex-standard-100-for-custom-fleece-blankets-class-ii-vs-class-i-r.html) are useful for BOM discipline, packing controls and chemical-screening language, but they are not substitutes for a biological evaluation tied to the intended medical-kit use.

Finished article, material and component evidence are not interchangeable

A common failure in kit sourcing files is treating fabric-only data as if they covered the finished article. They do not necessarily. Fabric evidence may support the evaluation, but the article placed near the patient includes sewing thread, labels, printed areas, edge tapes, patches, adhesive points and primary packaging. Any of those can alter what is extracted or what contacts skin in foreseeable use.

For a low-complexity blanket with plain dyed fabric, polyester thread, no print and no adhesive labels, material evidence can sometimes be strong enough for the legal manufacturer’s assessor to conclude that further endpoint testing is unnecessary. For a higher-complexity blanket with dark shades, large print coverage, transferred logos, antimicrobial finish, flame retardant, recycled blend variability or a fragranced pouch, fabric-only evidence is usually not enough because the assessed article is no longer the same as the tested substrate.

Buyers should ask for report matching at three levels. First, material level: fibre composition, dye class, finish chemistry and any coating or print system. Second, component level: thread, labels, patch materials, zippers or closures if any, and packaging-contact materials. Third, finished article level: actual construction, dimensions, weight band, colourway, packaging configuration and intended claim set. Weak files usually collapse these three into one generic supplier declaration.

Acceptable evidence packages typically show exact sample identity, lot or reference number, article description, colour or print reference, test standard, extraction conditions where relevant, issue date and issuing lab. Weak packages use phrases like "similar article", "same material family" or "representative blanket" without a controlled bridge rationale.

Separate biological evidence from textile-quality evidence

Biological-safety evidence, user-acceptance controls and ordinary textile QA are different workstreams. Keep them separate in the approval file. Biological evidence concerns the chemistry of fibres, dyes, finishes, labels, coatings, inks, adhesives and packaging-contact materials that could contribute extractables or leachables in use. Those belong in the biological evaluation and chemical-compliance rationale.

Textile-quality evidence concerns whether the blanket performs like the approved article. Typical checks include mass per area, dimensions, seam security, pilling, colourfastness, fabric-surface pH, odour on opening, lint shedding, wash stability and packaging integrity. These are commercial acceptance controls. They do not by themselves demonstrate biocompatibility.

For a 180gsm fleece blanket, a sensible textile-QA screen might include finished GSM check, dimensions, workmanship to AQL 2.5 for major defects as a commercial benchmark, pilling to ISO 12945 after an agreed cycle count such as 2,000 rubs or the applicable method endpoint, colourfastness to rubbing under ISO 105-X12 for dark shades, wash fastness under ISO 105-C06 where laundering claims apply, and packaging seal integrity checks. Those controls help prove manufacturing consistency and can indirectly support risk assessment by showing process stability. They are still not a substitute for biological evaluation.

pH, odour and AQL deserve careful language. Fabric pH and odour can indicate poor washing-off, finishing residue or packaging contamination, and AQL can show whether the lot was controlled. That makes them useful as consistency indicators. None of them is biocompatibility evidence on its own. A buyer should not accept a stack of pH, odour, wash and workmanship reports presented as "medical compliance".

What ISO 10993-1 actually asks you to do

ISO 10993-1 is a framework for biological evaluation based on the nature and duration of body contact, not a fixed shopping list of tests. The contact categories are typically grouped by tissue contact route, such as skin, mucosal membrane, breached or compromised surface, blood path indirect and implant contact, and then by contact duration: limited exposure of 24 hours or less, prolonged exposure of more than 24 hours to 30 days, and long-term exposure of more than 30 days. A trauma-kit blanket usually starts in the skin-contact discussion, not implant or blood-path logic, unless the intended use says otherwise.

Endpoint selection is risk-based. For low-risk skin-contact articles, the likely starting endpoints are cytotoxicity under ISO 10993-5, sensitization under ISO 10993-10 and irritation or intracutaneous reactivity logic now commonly addressed for skin-contact articles through ISO 10993-23 and related evaluation practice. Those endpoints are not automatic box-ticks. They are chosen, justified or waived through a biological evaluation under ISO 10993-1 using existing data, material characterization, toxicological assessment and intended use.

For procurement teams, ISO 10993-18 and ISO 10993-17 are often the practical centre of gravity. ISO 10993-18 covers chemical characterization of materials, which in textile terms means understanding the composition of the fabric and all patient-relevant components, then identifying substances that could be extracted under relevant conditions. ISO 10993-17 addresses the toxicological risk assessment of identified substances. In many intact-skin blanket programs, this chemistry-plus-toxicology route is more realistic than running a broad panel of endpoint tests on every colourway.

That is why buyers should tighten terminology. Ask for a biological evaluation strategy under ISO 10993-1 or for supplier evidence supporting that strategy. Do not ask whether the blanket is "ISO 10993 approved". A standalone endpoint report without a risk assessment tied to intended use is not the same as a biological evaluation conclusion.

When testing may be waived and when it probably will not be

For an intact-skin, limited-contact blanket with a simple BOM, no antimicrobial treatment, no fragrance, no direct wound claim and no unusual packaging chemistry, the legal manufacturer may be able to justify limited new testing or no new endpoint testing through biological evaluation. That usually relies on finished-article definition, chemical characterization, toxicological review, known history of use for comparable materials and tight change control.

Testing becomes more likely when the chemistry or exposure route becomes less predictable. Typical triggers are dark or heavily printed shades, large logo coverage in the contact area, antimicrobial or deodorizing claims, flame-retardant treatment, recycled fibre streams with variable input quality, adhesives, laminated labels, scented packaging, sterilization, prolonged or repeated patient contact, or any intended contact with compromised skin. These factors increase the amount of article-specific evidence the assessor usually needs.

Procurement should treat waivers as documented decisions, not verbal shortcuts. If no new endpoint testing is planned, the file should still show why: exact article definition, BOM, chemistry declarations, relevant material and component data, any prior matching test reports, toxicological review where required, and the legal manufacturer’s conclusion within the risk-management file. If that logic is absent, the program is not truly waived; it is simply under-documented.

Compromised-skin scenarios that change the plan

Compromised skin is not a vague caution. Think of blankets marketed or instructed for burn response, direct drape over open abrasions, wound-adjacent placement where exudate or damaged tissue can contact the textile, or emergency use where the blanket is expected to sit directly over injured tissue rather than over clothing or intact skin. Those are not minor wording changes. They can materially change the biological evaluation plan and may make plain brushed fleece unsuitable because of lint, surface fibre release, retained finishes or difficult-to-characterise prints and labels.

Foreseeable use matters as much as explicit marketing copy. If a trauma kit is sold to ambulance, tactical, industrial first-response or burn-response channels and the pack copy or imagery shows the blanket covering visibly injured skin, the assessor may treat compromised-skin contact as reasonably foreseeable even if the front-panel claim only says "warmth" or "protection". That changes dossier expectations and can move the article into a higher review tier.

For these programs, buyers should escalate early. Expect formal review by the legal manufacturer’s regulatory owner, tighter chemistry scrutiny under ISO 10993-18, more explicit toxicological assessment under ISO 10993-17, and a stronger chance of finished-article biological testing. At that point, textile convenience features such as printed logos, patch labels, fragrance, coated decorative trims or recycled-blend substitutions usually become liabilities rather than selling points.

Extractables and leachables logic for textile blankets

Buyers often hear extractables and leachables language in plastics and drug-device discussions, then assume it does not apply to textiles. It does apply, but proportionately. For a fleece blanket, the main question is what substances can migrate from fibres, dyes, finishes, labels, inks, adhesives and packaging into the user environment under reasonably foreseeable contact conditions such as skin contact, perspiration, heat, friction and short-term enclosure in a kit bag.

Most low-risk blanket programs do not start by ordering exhaustive analytical screens on every SKU. They usually start with material characterization and supplier disclosure: fibre and additive identity, dye and finish family, whether the fleece is virgin or recycled, whether print binders or heat transfers are present, what the sewing thread and labels are made from, and what primary packaging touches the article. That allows a toxicological assessor to decide whether the chemistry is already adequately understood or whether targeted analytical work is justified.

Where analytical work is needed, the point is relevance. A broad solvent extraction on unfinished fabric may tell less than a targeted review of the actual dark dyed, anti-pilled, bagged article. Buyers should ask how the tested sample matches the quoted article and whether colour, finish, label and packaging were included in the characterized configuration. Otherwise the report may understate real exposure contributors.

Chemistry procurement controls buyers should freeze at RFQ stage

A workable blanket compliance file starts with procurement controls, not late-stage testing. Freeze the article BOM before approval: fabric specification, yarn source if recycled claims are used, dye method, finish package, thread, labels, any print or transfer, bag film, master-carton ink and any insert paper that sits in direct contact. Require finish disclosure at least by chemistry family, for example silicone softener, anti-pilling resin, C0 water repellent if used, antimicrobial active if any, or flame-retardant package if any. "Standard soft finish" is not enough.

Link all evidence to colour and print status. Dark navy, black and red shades can carry different dye loads or rubbing behaviour from white or pastel articles. A printed logo over the patient-contact area adds ink, binder and curing chemistry that the plain fabric report does not cover. If the approved article is unprinted, keep it unprinted in the patient-contact zone unless the biological evaluation is updated.

Freeze packaging as part of the assessed article where relevant. For kit blankets, a 40 to 60 micron LDPE bag, a zip bag, a heat-sealed PE pouch or a vacuum pack can all change odour, volatile residue retention and contact with additives. If the blanket is packed compressed immediately after finishing, residual chemistry and odour risks are usually higher than after adequate airing and conditioning.

Build change-notification triggers into the purchase order and quality agreement. Require prior approval for changes to fibre source, recycled-content source, dyestuff supplier, finishing recipe, sewing thread, label type, print system, bag resin, slip additive package, sterilization status, production site or subcontractor. Without that clause, the buyer may be holding reports on one article and receiving another.

Adjacent compliance declarations buyers usually need in the same pack

The biological evaluation file is only one part of a usable procurement pack. Buyers commonly also request chemical and market-access declarations matched to destination market and brand policy. Typical asks are REACH SVHC declaration, REACH Annex XVII compliance where relevant, and any customer restricted substances list covering azo colorants, formaldehyde, heavy metals, phthalates, chlorinated carriers or other brand-specific concerns.

For U.S. programs, CPSIA tracking labels or CPSIA chemical screens may matter only if the blanket is sold for children’s use or enters a category where those rules apply. Proposition 65 review may matter for California channels depending on chemistry and exposure assumptions. These are destination-specific asks, not universal blanket requirements. The same applies to retailer RSLs, hospital system restricted-substance rules and distributor private standards.

A practical compliance pack for a medical-kit blanket therefore often contains: article specification, BOM, biological-evaluation support documents, REACH declarations, any destination-specific declarations, packaging specification, traceability records, artwork and claim approval, and change-control commitments. Keep these as one linked file set so purchasing does not approve the article while regulatory is still reviewing a different configuration.

Related chemical-screening references such as [reach-annex-xvii-checks-for-210d-pu-coated-picnic-mats-restricted-subs](/blog/reach-annex-xvii-checks-for-210d-pu-coated-picnic-mats-restricted-subs.html), [azo-dye-screening-for-250gsm-printed-mink-polyester-throws-when-u-s-pr](/blog/azo-dye-screening-for-250gsm-printed-mink-polyester-throws-when-u-s-pr.html) and [textile-certifications-explained-buyers](/blog/textile-certifications-explained-buyers.html) are useful for procurement language on declarations and report matching, but the medical-kit buyer still needs article-specific biological evaluation support.

Red-flag claims and features that trigger higher review

Escalate the review tier if any of the following appears in the RFQ, artwork, sales sheet or supplier proposal: antimicrobial, antibacterial, anti-odor, skin-friendly claim without evidence route, soothing treatment, aloe, fragrance, medicated finish, burn blanket wording, wound coverage wording, sterile or sterilizable status, direct patient care claim, flame retardant, printed logo across the main contact area, recycled-content substitution without source controls, or any statement implying use on broken skin.

These are not just marketing details. Each one changes either regulatory positioning, chemistry profile, foreseeable exposure or both. An antimicrobial finish can introduce active substances and claim substantiation issues. Fragrance adds volatile chemistry. Flame retardants can materially change the toxicological picture. Recycled input streams may need tighter source control and declaration discipline than virgin polyester. Sterilization can alter materials and packaging, and it changes the evidence route entirely.

For sourcing teams, the practical rule is simple: if the feature would be highlighted in a sales meeting, it probably needs to be highlighted in the compliance review too.

Decision matrix for sourcing approval

Use a simple approval matrix. Route A: general warmth blanket inside a first-aid kit, intact-skin contact only, limited exposure up to 24 hours, simple BOM, no print in contact area, no special finish, no sterilization. Typical evidence route: controlled article specification, full BOM, supplier chemistry declarations, REACH and customer-RSL declarations, packaging specification, prior matching material or article reports if available, and biological evaluation conclusion by the legal manufacturer based mainly on chemistry review and risk assessment.

Route B: same blanket but dark shade, recycled fibre, printed logo, multiple labels or compressed retail pouch. Evidence route: all Route A documents plus tighter colour- and component-specific linkage, stronger change control, and likely more detailed material characterization review under ISO 10993-18. A legal manufacturer may still conclude no new endpoint testing is needed, but the rationale has to be article-specific.

Route C: warmth or thermal-management claim with prolonged contact, institutional repeat use, or direct user-contact concerns driven by packaging or finish chemistry. Evidence route: Route B plus more formal toxicological assessment under ISO 10993-17 and a higher chance of requesting finished-article endpoint data or additional analytical work.

Route D: burn-care, compromised-skin, wound-adjacent, sterile, antimicrobial or other elevated-claim blanket. Evidence route: regulatory escalation before sourcing release. Expect a formal biological evaluation tied to intended use, likely finished-article evidence, and possible rejection of standard fleece construction for that application.

Worked example: RFQ to release

A distributor sends an RFQ for a 125 x 150cm, 180gsm black polyester fleece blanket packed inside an industrial trauma kit. Initial sales wording says "for warmth and comfort". The buyer asks for article spec, BOM, dye and finish disclosure, thread and label details, packaging spec, REACH SVHC declaration, Annex XVII declaration where relevant, change-control commitment and any prior ISO 10993-related evidence. The supplier returns a fabric data sheet, a generic Oeko-Tex certificate, a pilling report and a cytotoxicity report on a different 220gsm white fleece article.

That file is not enough. The buyer rejects the unmatched cytotoxicity report because fabric weight, colour and article construction do not match. The Oeko-Tex certificate may support chemical-control confidence, but it is not a biological evaluation. The buyer requests black-colour linkage, confirmation of no print in contact area, no antimicrobial or fragrance finish, the actual packaging film spec and a declaration that the approved BOM covers fabric, thread, label and polybag.

The legal manufacturer then reviews the intended claim and confirms intact-skin, limited-contact use only. Based on the simple BOM, controlled chemistry, matching declarations and packaging disclosure, its assessor may conclude that the biological evaluation under ISO 10993-1 can rely on existing information and chemical-risk review without new endpoint testing. The article is released with a change-notification clause. Two months later, the supplier proposes a printed logo transfer and a new recycled polyester source. That triggers re-review before approval because the assessed article has changed.

Supplier document checklist: acceptable versus weak evidence

Acceptable file set: signed article specification with dimensions, GSM and construction; full BOM covering fabric, thread, labels, print, adhesives and packaging; finish disclosure by chemistry family; colour and print reference; declarations for REACH SVHC and any applicable Annex XVII or customer RSL; prior matching chemical or biological reports with exact sample identity; packaging specification; traceability and lot coding method; and written change-control commitment. If previous biological evidence exists, it should identify the tested article clearly and show why it is relevant to the current configuration.

Weak file set: generic polyester declaration, unrelated fabric report, expired or unmatched certificate, broad statement of "medical grade" with no standard referenced, endpoint report lacking sample description, or a quality file containing only pH, wash fastness, pilling and workmanship inspection. Those documents may be useful for commercial QA, but they do not close the biological-evaluation question.

For lot release, add routine controls such as incoming material identity check, workmanship inspection to agreed AQL level, GSM and size verification, packaging and label verification, and retention sample storage by lot. These are manufacturing controls, not regulatory conclusions, but they stop drift between the article approved by regulatory and the article shipped by production.

Commercial controls that support consistency but are not regulatory thresholds

Buyers often ask for hard numbers. Use them as commercial controls unless your legal manufacturer states otherwise. For a standard 180gsm fleece blanket, common commercial tolerances might be finished mass within about +/-5%, size within about +/-2cm, workmanship to AQL 2.5 for major defects and AQL 4.0 for minor defects, and seam security appropriate to construction and handling. Those are not ISO 10993 thresholds and should never be described as such.

The same applies to pilling, crocking and odour. You may specify pilling performance under an agreed ISO 12945 method, rubbing fastness under ISO 105-X12, or odour acceptance after sealed-pack conditioning, but those are programme-specific quality requirements. They help maintain article consistency and reduce complaint risk. They do not, by themselves, establish safety for the intended medical use.

Keep the distinction explicit in the specification and the PO. Put regulatory evidence asks in one section and commercial acceptance criteria in another. That makes supplier accountability clearer and reduces the risk of a mill answering a biological-evaluation request with only QA data.

Final buyer checklist before release

Before approving a trauma-kit fleece blanket, confirm the following exact asks are on file: intended-use and claims text for the destination market; signed article specification with size, GSM, construction and colourway; full BOM including fabric, thread, labels, print, adhesives and packaging; dye and finish disclosure; statement on antimicrobial, fragrance, flame-retardant and sterilization status; packaging specification and contact materials; prior biological or chemical reports matched to the current article where available; REACH SVHC declaration and any applicable Annex XVII, CPSIA, Prop 65 or customer-RSL declarations; change-notification triggers; traceability method; and the legal manufacturer’s biological-evaluation conclusion or review status.

If any one of those items is missing, the sourcing file is incomplete. The supplier can support the evidence route, but the legal manufacturer or regulatory owner still has to sign off classification, claims, risk management linkage and the final biological evaluation conclusion under ISO 10993-1. That division of responsibility should be written into the project from the start, not reconstructed after the first audit question.

For adjacent sourcing guidance on controlled fleece specifications and evidence discipline, see [180gsm-polyester-fleece-blankets-with-overlocked-edges-for-disaster-re](/blog/180gsm-polyester-fleece-blankets-with-overlocked-edges-for-disaster-re.html), [blanket-care-washing-guide](/blog/blanket-care-washing-guide.html), [custom-blanket-decoration-methods](/blog/custom-blanket-decoration-methods.html) and [aql-2-5-inspection-checklist-for-200gsm-coral-fleece-promotional-blank](/blog/aql-2-5-inspection-checklist-for-200gsm-coral-fleece-promotional-blank.html) where the controls are relevant to article consistency and report matching.

Frequently asked

Does a trauma-kit blanket automatically need ISO 10993 testing? No. A blanket inside a trauma or first-aid kit does not automatically require a broad endpoint test panel. The starting point is intended use, body-contact category, contact duration, chemistry of the finished article and destination-market regulatory strategy. Many intact-skin, limited-contact blanket programs are handled through a biological evaluation under ISO 10993-1 using controlled BOM data, chemical characterization under ISO 10993-18, toxicological assessment under ISO 10993-17 where needed, and matching supplier declarations rather than default testing of every endpoint.

What ISO 10993 endpoints are most relevant for a fleece blanket? For a skin-contact blanket, the likely discussion usually starts with cytotoxicity under ISO 10993-5, sensitization under ISO 10993-10 and irritation logic commonly addressed for skin-contact articles under ISO 10993-23. Whether those endpoints need new testing depends on intended use, contact duration, chemistry complexity, existing data and the legal manufacturer's biological evaluation. A simple intact-skin blanket may be justified through risk assessment and chemistry review without running all three as new tests.

Can fabric-only reports support approval of the finished blanket? Sometimes, but only if the legal manufacturer can justify that the finished article is materially equivalent to the tested substrate. Fabric-only data become weak once the article adds dark dyes, heavy print coverage, labels, adhesive patches, special finishes, unusual packaging or recycled-source variability. Buyers should request evidence at material, component and finished-article level and reject reports that do not match the actual quoted construction.

Are pH, odour, pilling and AQL inspection enough for medical-kit approval? No. Those are quality and consistency controls, not biocompatibility evidence. They can still help indirectly by showing stable manufacturing and acceptable lot quality, but they do not replace biological evaluation, chemical declarations or toxicological assessment tied to intended use. Treat them as commercial acceptance criteria, not regulatory proof.

What should trigger regulatory escalation before sourcing release? Escalate if the blanket has antimicrobial or anti-odor claims, fragrance, flame-retardant treatment, printed logos in the contact area, recycled-content changes without source control, sterilization, burn-care or wound-adjacent positioning, or any likely contact with compromised skin. Those features usually increase chemistry complexity, alter foreseeable exposure or change regulatory positioning, so the legal manufacturer may need a more formal ISO 10993-1 biological evaluation and possibly finished-article testing.

Who signs off the final compliance decision? The supplier provides article specifications, BOM disclosure, chemical declarations, supporting reports and change-control commitments. The final classification decision, intended-use wording, risk-management linkage and biological evaluation conclusion belong to the legal manufacturer or regulatory owner placing the finished kit on the market. Buyers should make that ownership explicit in the project file.

Have a project in mind? Send us your spec — we'll reply within one business day with indicative pricing and a sample plan.

Related